BrainsWay (BWAY) News
NASDAQ: BWAYHealth CareMedical/Dental InstrumentsUSD
8.48-0.25 (-2.86%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BWAY news summary
We found 11 recent headlines mentioning BrainsWay (BWAY): 0 in the past week and 8 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, BWAY is down 2.86% at $8.48. The most recent story, "BrainsWay: 3 Key Takeaways for Long-Term Investors", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BrainsWay headlines
- BrainsWay: 3 Key Takeaways for Long-Term InvestorsKey PointsBrainsWay shipped 130 Deep TMS systems in the third quarter.Nasdaq
- BrainsWay (BWAY) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- BrainsWay Reports Third Quarter 2026 Financial Results and Operational HighlightsRevenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 millionGlobeNewswire
- BrainsWay Announces Strategic Collaboration with Mindful Health SolutionsLatest Collaboration Comes Amid Progress in Other Strategic Initiatives, Including Follow-on Investment in Earlier Minority Stake Investment Target Latest Collaboration Comes Amid Progress in Other…GlobeNewswire
- BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation…GlobeNewswire
- BrainsWay Ltd. Amends Notice of Annual General Meeting Scheduled for November 25, 2026BrainsWay Ltd. filed an amendment to its annual general meeting notice on Form 6-K/A to reflect that Dr. David Zacut notified the company on October 25, 2026, that he does not intend to stand for…Nasdaq
- BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million LivesBURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation…GlobeNewswire
- BrainsWay - Depositary Receipt Price Target Increased by 218.89% to $0.20The average one-year price target for BrainsWay - Depositary Receipt (NASDAQGM:BWAY) has been revised to $0.20 / share. This is an increase of 218.89% from the prior estimate of $0.06 dated October…Nasdaq
- BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical GroupPartnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern…GlobeNewswire
- BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered LivesBURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation…GlobeNewswire
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.NasdaqAXGN, AZN, BJDX, BMRN